e-Lung Computed Tomography Biomarker Stratifies Patients at Risk of Idiopathic Pulmonary Fibrosis Progression in a 52-Week Clinical Trial.

Anand DevarajFinja OttinkChristian Rennison-JonesFrançois-Xavier BléOlivier JolyAdnan AzimStephen GerryGeorge HarstonKristoffer OstridgePeter M George

Published in: American journal of respiratory and critical care medicine (2024)

Keyphrases

idiopathic pulmonary fibrosis
clinical trial
computed tomography
positron emission tomography
interstitial lung disease
phase ii
double blind
magnetic resonance imaging
placebo controlled
study protocol
open label
dual energy
contrast enhanced
phase iii
image quality
randomized controlled trial